RT Journal Article
SR Electronic
T1 Cytotoxic Activity of Isoniazid Derivative in Human Breast Cancer Cells
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2675
OP 2685
DO 10.21873/invivo.12551
VO 35
IS 5
A1 MUTTIAH BARATHAN
A1 AHMAD KHUSAIRY ZULPA
A1 KUMUTHA MALAR VELLASAMY
A1 VANITHA MARIAPPAN
A1 NAVEEN KUMAR HAWALA SHIVASHEKAREGOWDA
A1 ZARIDATUL AINI IBRAHIM
A1 JAMUNA VADIVELU
YR 2021
UL http://iv.iiarjournals.org/content/35/5/2675.abstract
AB Background/Aim: Isoniazid is an antibiotic used for the treatment of tuberculosis. Previously, we found that the isoniazid derivative (E)-N’-(2,3,4-trihydroxybenzylidene) isonicotinohydrazide (ITHB4) could be developed as novel antimycobacterial agent by lead optimization. We further explored the ability of this compound compared to zerumbone in inhibiting the growth of MCF-7 breast cancer cells. Materials and Methods: Cytotoxicity was measured by the MTT assay and further confirmed via apoptosis, ROS, cell cycle, DNA fragmentation and cytokine assays. Results: ITHB4 demonstrated a lower IC50 compared to zerumbone in inhibiting the proliferation of MCF-7 cells. ITHB4 showed no toxicity against normal breast and human immune cells. Apoptosis assay revealed that ITHB4, at a concentration equal to the IC50, induces apoptosis of MCF-7 cells and cell cycle arrest at the sub-G1 and G2/M phases. ITHB4 triggered accumulation of intracellular ROS and nuclear DNA fragmentation. Secretion of pro-inflammatory cytokines induced inflammation and potentially immunogenic cell death. Conclusion: ITHB4 has almost similar chemotherapeutic properties as zerumbone in inhibiting MCF-7 growth, and hence provide the basis for further experiments in animal models.